• Ascendis Pharma released week-104 radiographic results from the pivotal ApproaCH trial of TransCon CNP in children with achondroplasia.
• Trial met its week-52 primary endpoint, with annualized growth velocity LS mean difference of 1.49 cm/year vs placebo (95% CI 1.05-1.93; P<0.0001).
• Growth gains were maintained through week 104, with observed annualized growth velocity around 5.65 cm/year for continuous treatment.
• Lower-limb alignment improved, with tibial-femoral angle treatment difference of -1.81 degrees vs placebo at week 52; reductions continued through week 104.
• Safety through week 104 showed no discontinuations; injection-site reactions occurred in 20.2% of treated children.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.